PGAP3

Across TCGA pan-cancer cohorts, PGAP3 Mutation is linked to patient survival in 2 of 34 cancer types, making it a survival-associated PGAP3 data layer compared with 24 for mass-spec protein and 2 for mass-spec protein.

The strongest signal is observed in cervical squamous cell carcinoma and endocervical adenocarcinoma (CESC), where higher PGAP3 Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated PGAP3 expression acts as an unfavorable survival marker.

CESC and SKCM are the cancer types where PGAP3 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CESC	DFS	Median	II,III,IV	0.193	0.705	.045	6	view →
SKCM	OS	Median	All	0.448	0.783	.037	3	view →

Pink = unfavorable, green = favorable. Showing the 2 strongest of 2 lineages.

PGAP3–CESC (DFS)

Open the CESC breakdown →